Structure Therapeutics' oral weight-loss drug shows 16% body fat reduction in trials
Structure Therapeutics has released positive results from its phase 2 trials of aleniglipron, an oral drug for weight loss. The company's shares climbed around 8% in Monday trading after the announcement. Investors have shown strong confidence, with the stock rising roughly 184% since the start of the year.
The latest data comes from three studies: the 44-week ACCESS II trial, an interim body composition study, and an open-label extension. In ACCESS II, patients on 180 mg and 240 mg doses lost an average of 16.3% and 16% of their body weight, respectively, compared to placebo. No signs of a weight loss plateau appeared in either trial.
In the open-label extension, participants taking 120 mg of alenigliptin continued losing weight, reaching a 16.2% reduction at 56 weeks. The company described the results as promising and confirmed plans to start phase 3 trials in the second half of 2026. The stock has seen significant growth, trading between $63 and $89 after hitting a 52-week high of $94.90. This marks a sharp rise from its low of $13.22 over the past year.
Structure Therapeutics now prepares for phase 3 testing of aleniglipron later in 2026. The drug's performance in phase 2, with sustained weight loss and no plateau, supports its potential as an obesity treatment. The company's stock surge reflects investor optimism about its progress.
